TSG11
MCID: TMR016
MIFTS: 29

Tumor Suppressor Gene on Chromosome 11 (TSG11)

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Tumor Suppressor Gene on Chromosome 11

MalaCards integrated aliases for Tumor Suppressor Gene on Chromosome 11:

Name: Tumor Suppressor Gene on Chromosome 11 56 13 71
Nonsmall Cell Lung Cancer Suppressor 56
Non-Small Cell Lung Carcinoma 71
Nonsmall Cell Lung Cancer 56
Tsg11 56

Classifications:



External Ids:

OMIM 56 603040
UMLS 71 C0007131 C1864232

Summaries for Tumor Suppressor Gene on Chromosome 11

MalaCards based summary : Tumor Suppressor Gene on Chromosome 11, also known as nonsmall cell lung cancer suppressor, is related to lung cancer and neutropenia. An important gene associated with Tumor Suppressor Gene on Chromosome 11 is TSG11 (Tumor Suppressor Gene On Chromosome 11). The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and brain.

More information from OMIM: 603040

Related Diseases for Tumor Suppressor Gene on Chromosome 11

Diseases related to Tumor Suppressor Gene on Chromosome 11 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 lung cancer 12.7
2 neutropenia 10.9
3 adenocarcinoma 10.8
4 esophagitis 10.7
5 lung cancer susceptibility 3 10.7
6 large cell carcinoma 10.6
7 lung disease 10.6
8 exanthem 10.5
9 mucositis 10.5
10 squamous cell carcinoma 10.5
11 interstitial lung disease 10.5
12 virus-associated trichodysplasia spinulosa 10.5
13 bronchiolo-alveolar adenocarcinoma 10.4
14 thrombocytopenia 10.4
15 alopecia 10.4
16 retinoblastoma 10.3
17 familial retinoblastoma 10.3
18 peripheral nervous system disease 10.3
19 neuropathy 10.3
20 lymph node disease 10.3
21 xeroderma pigmentosum, variant type 10.3
22 pneumothorax 10.3
23 constipation 10.3
24 idiopathic interstitial pneumonia 10.3
25 pulmonary fibrosis 10.3
26 stomatitis 10.3
27 granulocytopenia 10.3
28 dysphagia 10.3
29 neurofibromatosis, type ii 10.2
30 breast cancer 10.2
31 ataxia-telangiectasia 10.2
32 thrombocytopenia 3 10.2
33 ataxia and polyneuropathy, adult-onset 10.2
34 familial adenomatous polyposis 10.2
35 respiratory failure 10.2
36 telangiectasis 10.2
37 glioblastoma multiforme 10.2
38 lung squamous cell carcinoma 10.2
39 hyperglycemia 10.2
40 pulmonary coin lesion 10.2
41 lymphopenia 10.2
42 severe combined immunodeficiency 10.2
43 b-cell lymphoma 10.2
44 rapidly involuting congenital hemangioma 10.2
45 autoimmune disease 10.0
46 bladder cancer 10.0
47 colorectal cancer 10.0
48 hepatocellular carcinoma 10.0
49 leukemia, chronic lymphocytic 10.0
50 pulmonary fibrosis, idiopathic 10.0

Graphical network of the top 20 diseases related to Tumor Suppressor Gene on Chromosome 11:



Diseases related to Tumor Suppressor Gene on Chromosome 11

Symptoms & Phenotypes for Tumor Suppressor Gene on Chromosome 11

Clinical features from OMIM:

603040

Drugs & Therapeutics for Tumor Suppressor Gene on Chromosome 11

Drugs for Tumor Suppressor Gene on Chromosome 11 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
3
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
4
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
5 Flurbiprofen axetil Investigational Phase 4 91503-79-6
6 Hormones Phase 4
7 Antiemetics Phase 4
8 Gastrointestinal Agents Phase 4
9 Anti-Inflammatory Agents Phase 4
10 glucocorticoids Phase 4
11 Hormone Antagonists Phase 4
12 Anesthetics Phase 4
13 Analgesics Phase 4
14 Antirheumatic Agents Phase 4
15 HIV Protease Inhibitors Phase 4
16
protease inhibitors Phase 4
17 BB 1101 Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Autonomic Agents Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Central Nervous System Depressants Phase 4
24 Anesthetics, General Phase 4
25 Narcotics Phase 4
26 Adjuvants, Anesthesia Phase 4
27 Dexamethasone 21-phosphate Phase 4
28 Anesthetics, Intravenous Phase 4
29 Analgesics, Opioid Phase 4
30
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
31
Ifosfamide Approved Phase 3 3778-73-2 3690
32
Dalteparin Approved Phase 3 9005-49-6
33
Pancrelipase Approved, Investigational Phase 3 53608-75-6
34
Nadroparin Approved, Investigational Phase 3
35
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
36
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
37
Mesna Approved, Investigational Phase 3 3375-50-6 598
38
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
39
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
40
Ethanol Approved Phase 2, Phase 3 64-17-5 702
41
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
42
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
43
tannic acid Approved Phase 3 1401-55-4
44
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
45
Gemcitabine Approved Phase 3 95058-81-4 60750
46
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
47
Ceritinib Approved Phase 3 1032900-25-6
48
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
49
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
50
Tegafur Approved, Investigational Phase 3 17902-23-7 5386

Interventional clinical trials:

(show top 50) (show all 461)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
2 A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
3 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Recruiting NCT03853551 Phase 4 Osimertinib
4 Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX) Not yet recruiting NCT03134456 Phase 4 Pembrolizumab Injection
5 Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Long-term Survival After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial Terminated NCT03172988 Phase 4 Dexamethasone;Normal saline;Flurbiprofen axetil;Lipid microsphere
6 Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01301560 Phase 3
7 A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection(Dulanermin for Injection)in the Treatment of Advanced Non-small Cell Lung Cancer Unknown status NCT03083743 Phase 3
8 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001) Unknown status NCT01158170 Phase 3 Erlotinib /Gefitinib
9 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
10 Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC) Unknown status NCT02879097 Phase 3 Carboplatin;Paclitaxel
11 Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy Completed NCT00864331 Phase 3 Chemotherapy
12 A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol. Completed NCT00035152 Phase 3 Paclitaxel and carboplatin
13 An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non Small Cell Lung Cancer Completed NCT00049998 Phase 3 topotecan
14 Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT00080340 Phase 3 TLK286 (Telcyta) HCl for Injection;gefitinib (Iressa)
15 Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. Completed NCT00148395 Phase 3 Gemcitabine;Navelbine;Carboplatin;Cisplatin;Mitomycin;Ifosfamide
16 Non-small Cell Lung Cancer Study US75 (Z-PACT) Completed NCT00086268 Phase 3 zoledronic acid;Taxotere;Carboplatin
17 A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Completed NCT00076388 Phase 3 Gefitinib;Docetaxel
18 The Impact of Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer: A Prospective Randomized Clinical Trial (PET START Trial) Completed NCT00136864 Phase 3
19 A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Completed NCT00404924 Phase 3 ZD6474 (vandetanib)
20 Randomized Controlled Trial to Evaluate Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatine in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer (JCOG0301, NCSLC-Elderly-CBDCA-RT Phase III) Completed NCT00132665 Phase 3 B: CBDCA and Radiotherapy
21 A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00540514 Phase 3 Albumin-bound paclitaxel;Paclitaxel;Carboplatin
22 A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Completed NCT00112294 Phase 3 Paclitaxel (Taxane);Docetaxel (Taxane);Carboplatin;Cetuximab
23 A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed NCT00087711 Phase 3 pemetrexed;gemcitabine;cisplatin
24 A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate Completed NCT00312013 Phase 3 Nadroparin
25 A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer Completed NCT00622349 Phase 3 Cisplatin, Ifosfamide, Gemcitabine;Ifosfamide, Gemcitabine;Cisplatin, docetaxel
26 A Randomized Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion as Second-Line Treatment of Patients With Advanced Nonsmall Cell Lung Cancer Completed NCT00005093 Phase 3 gemcitabine hydrochloride;tacedinaline
27 Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients Completed NCT00478699 Phase 3 Docetaxel/Cisplatin;Docetaxel;Gemcitabine/Cisplatin;Docetaxel/Cisplatin
28 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
29 The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-small Cell Lung Cancers: A Prospective Multicentre Randomized Clinical Trial Completed NCT00136890 Phase 3
30 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
31 Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine Completed NCT00312819 Phase 2, Phase 3 chemotherapy +/- disulfiram
32 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors Completed NCT00373425 Phase 3 Erlotinib;Placebo
33 A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease. Completed NCT00409188 Phase 3 Single low dose cyclophosphamide;Placebo
34 Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
35 Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy Recruiting NCT02864251 Phase 3 Pemetrexed;Cisplatin;Carboplatin
36 LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Recruiting NCT02973789 Phase 3 Immune checkpoint inhibitors or docetaxel
37 A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA). Active, not recruiting NCT02511106 Phase 3 AZD9291 80 mg/40 mg;Placebo AZD9291 80 mg/40 mg
38 A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
39 A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
40 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) Active, not recruiting NCT02453282 Phase 3 Paclitaxel + Carboplatin;Gemcitabine + Cisplatin;Gemcitabine + Carboplatin;Pemetrexed + Cisplatin;Pemetrexed + Carboplatin
41 A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer Active, not recruiting NCT03003962 Phase 3 Durvalumab (MEDI4736);Paclitaxel + carboplatin;Gemcitabine + cisplatin;Gemcitabine + carboplatin;Pemetrexed + cisplatin;Pemetrexed + carboplatin
42 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Active, not recruiting NCT02542293 Phase 3 Paclitaxel + carboplatin;Gemcitabine + cisplatin;Gemcitabine + carboplatin;Pemetrexed + cisplatin;Pemetrexed + carboplatin
43 A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) Active, not recruiting NCT02578680 Phase 3 Cisplatin;Carboplatin;Pemetrexed;Dexamethasone 4 mg;Saline solution
44 A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer Active, not recruiting NCT02737501 Phase 3 Brigatinib;Crizotinib
45 Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib Active, not recruiting NCT02416739 Phase 2, Phase 3 Nicotinamide
46 A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) Active, not recruiting NCT03950674 Phase 3 Cisplatin;Carboplatin;Pemetrexed;Dexamethasone 4 mg;Saline solution
47 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00324805 Phase 3 Cisplatin;Docetaxel;Gemcitabine Hydrochloride;Pemetrexed Disodium;Vinorelbine Tartrate
48 A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT02438722 Phase 2, Phase 3 Afatinib Dimaleate
49 A Randomized Open-Label Phase III Trial of MK-3475 Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer Active, not recruiting NCT02142738 Phase 3 Pembrolizumab;Paclitaxel;Carboplatin;Pemetrexed;Cisplatin;Gemcitabine
50 Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer Not yet recruiting NCT03700333 Phase 3 S-1 therapy;Pemetrexed therapy

Search NIH Clinical Center for Tumor Suppressor Gene on Chromosome 11

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Afatinib
afatinib dimaleate
ceritinib
crizotinib
docetaxel
erlotinib
gefitinib
hydroxyurea
irinotecan
Irinotecan hydrochloride
pembrolizumab
Topotecan
Topotecan Hydrochloride
trametinib
vinorelbine
Vinorelbine tartrate

Genetic Tests for Tumor Suppressor Gene on Chromosome 11

Anatomical Context for Tumor Suppressor Gene on Chromosome 11

MalaCards organs/tissues related to Tumor Suppressor Gene on Chromosome 11:

40
Lung, Breast, Brain, Prostate, Testes, T Cells, Colon

Publications for Tumor Suppressor Gene on Chromosome 11

Articles related to Tumor Suppressor Gene on Chromosome 11:

(show all 17)
# Title Authors PMID Year
1
Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q. 56
9653156 1998
2
Allelic losses in human chromosome 11 in lung cancers. 56
7541642 1995
3
Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. 56
8098218 1993
4
Unexpected Findings in a Child with Atypical Hemolytic Uremic Syndrome: An Example of How Genomics Is Changing the Clinical Diagnostic Paradigm. 61
28589114 2017
5
Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. 61
10336639 1999
6
Localization and characterization of a chromosome 11 tumor suppressor gene using organotypic raft cultures. 61
9067287 1997
7
Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. 61
8784062 1996
8
Genetic heterogeneity of chromosome 11 associated with tumorigenicity in HeLa D98-OR cells. 61
8548745 1995
9
Allelotyping in Wilms tumors identifies a putative third tumor suppressor gene on chromosome 11. 61
7558032 1995
10
Different characteristics of hepatoid and non-hepatoid alpha-fetoprotein-producing gastric carcinomas: an experimental study using xenografted tumors. 61
7519587 1994
11
Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. 61
7906100 1994
12
Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. 61
1639957 1992
13
Altered neurovirulence of temperature-sensitive vesicular stomatitis virus mutants in a murine model by inoculation of bombesin: a neuropeptide. I. Clinical, virological and pathological observations. 61
2538576 1989
14
Neuropeptide-induced hypothermia and the course of central nervous system disease mediated by temperature-sensitive mutants of vesicular stomatitis virus. 61
2991582 1985
15
Analysis of the defects of temperature-sensitive mutants of vesicular stomatitis virus: intracellular degradation of specific viral proteins. 61
191641 1977
16
Progeny resulting from complementation between mutants of vesicular stomatitis virus. 61
163131 1975
17
Screening procedure for complementation-dependent mutants of vesicular stomatitis virus. 61
163345 1975

Variations for Tumor Suppressor Gene on Chromosome 11

Expression for Tumor Suppressor Gene on Chromosome 11

Search GEO for disease gene expression data for Tumor Suppressor Gene on Chromosome 11.

Pathways for Tumor Suppressor Gene on Chromosome 11

GO Terms for Tumor Suppressor Gene on Chromosome 11

Sources for Tumor Suppressor Gene on Chromosome 11

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....